K.C. Pharmaceuticals Recalls 589,848 Artificial Tears Bottles Over Sterility Concerns, Impacting Major US Brands
K.C. Pharmaceuticals, Inc. has initiated a Class II recall for 589,848 bottles of Artificial Tears Sterile Lubricant Eye Drops due to a critical "Lack of Assurance of Sterility." This nationwide U.S. recall, affecting multiple major brands including Leader and Good Sense, demands immediate action from procurement and supply chain leaders. Businesses must assess their exposure to K.C. Pharmaceuticals, Inc. and expedite qualification of alternative ophthalmic product manufacturers to mitigate supply disruption and patient safety risks.
Critical Sterility Assurance Failure Prompts Nationwide K.C. Pharmaceuticals Recall
K.C. Pharmaceuticals, Inc., based in Pomona, California, has initiated a Class II recall (D-0416-2026) for 589,848 bottles of its Artificial Tears Sterile Lubricant Eye Drops. The critical reason for this voluntary, firm-initiated recall, which began on March 3, 2026, is a "Lack of Assurance of Sterility." This deficiency poses a significant risk, particularly for an ophthalmic product intended for direct application to the eye, where microbial contamination can lead to severe infections, vision impairment, or even blindness. The recalled products contain active ingredients polyvinyl alcohol 0.5% and povidone 0.6%, formulated as a 0.5 FL OZ (15 mL) solution. The affected lots include AT24D01 (Exp. 04/30/26), AT24E01, AT24E02 (Exp. 05/31/26), and AT24G01 (Exp. 07/31/26), distributed under various brand names. For procurement directors and regulatory affairs heads, this event underscores the paramount importance of robust quality management systems and sterility validation protocols for all sterile drug products. Failure to ensure sterility assurance can lead to extensive product recalls, significant financial losses, reputational damage, and severe patient safety consequences, necessitating immediate review of supplier qualification and ongoing monitoring programs for similar products in your portfolio.
K.C. Pharmaceuticals, Inc. Facility Profile and Product Scope
The recalling firm, K.C. Pharmaceuticals, Inc., operates from its facility at 3420 Pomona Blvd, Pomona, CA 91768-3236, in the United States. This facility serves as a manufacturer for a substantial volume of over-the-counter (OTC) ophthalmic drug products, specifically artificial tears. The recalled product, Artificial Tears Sterile Lubricant Eye Drops, is a human OTC drug with the generic name polyvinyl alcohol and povidone, and is administered via the ophthalmic route. The broad reach of this recall, encompassing nearly 600,000 bottles, highlights K.C. Pharmaceuticals, Inc.'s significant role as a contract manufacturer or primary supplier for numerous private label and store brand artificial tears products across the U.S. market. For business development executives, this event signals potential shifts in market share and supplier relationships within the OTC ophthalmic segment. Companies relying on K.C. Pharmaceuticals, Inc. for their artificial tears supply must immediately assess the impact on their product availability and explore alternative manufacturing partnerships to maintain market presence and consumer trust. The facility's output, distributed nationwide, indicates its previous capacity to meet large-scale demand, making its current compliance issues particularly disruptive.
Extensive Supply Chain Exposure: Major Brands Impacted by Sterility Recall
The K.C. Pharmaceuticals, Inc. recall has created significant supply chain exposure across the United States, impacting a diverse array of major distributors and retail brands. The 589,848 bottles of Artificial Tears Sterile Lubricant Eye Drops were distributed nationwide under at least eight distinct brand names, demonstrating the widespread reliance on K.C. Pharmaceuticals, Inc. as a supplier. Key brands affected include: a) LEADER (NDC 70000-0011-1), distributed by Cardinal Health, Dublin, Ohio; b) Good Sense (NDC 50804-110-01), distributed by Perrigo Direct, Inc., Peachtree City, GA; c) Good Neighbor Pharmacy (NDC 24385-006-05), distributed by AmerisourceBergen, Conshohocken, PA; d) TopCare health (UPC 0 36800 09331 7), distributed by Topco Associates LLC, Elk Grove Village, IL; e) Best Choice (UPC 0 70038 47008 3), distributed by Valu Merchandisers, Co., Kansas City, KS; f) Kroger (UPC 0 11110 38600 7), distributed by The Kroger Co., Cincinnati, OH; g) P (UPC 0 41415 00976 9), distributed by Publix Super Markets, Inc., Lakeland, FL; and h) Quality Choice (NDC 83324-189-14), distributed by CDMA Inc., Novi, MI. This extensive list means that procurement directors and supply chain VPs across these organizations must swiftly identify and quarantine affected stock, manage returns, and navigate potential product shortages. The commercial implications are substantial, requiring immediate communication strategies for retailers and consumers, alongside efforts to secure alternative compliant supply sources to minimize market disruption and maintain brand integrity.
Mitigating Ophthalmic Product Risk: Identifying Alternative Suppliers
Given the critical nature of a sterility assurance failure for an ophthalmic product like Artificial Tears Sterile Lubricant Eye Drops (polyvinyl alcohol, povidone), procurement teams must immediately prioritize identifying and qualifying alternative suppliers. ChemLifeIntel's knowledge graph does not currently list specific alternative suppliers for K.C. Pharmaceuticals, Inc., underscoring the urgency for companies impacted by this recall to conduct their own comprehensive due diligence. This process should involve a rigorous assessment of potential manufacturers' quality systems, manufacturing capabilities, and regulatory compliance history, with a particular focus on their sterile manufacturing environments and validation protocols. Geographic diversity in sourcing should also be a key consideration to build resilience against future localized supply chain disruptions. Qualification timelines for new sterile product suppliers can be lengthy, often spanning several months due to the stringent regulatory requirements for facility audits, process validation, and analytical testing. Therefore, proactive engagement with potential alternative manufacturers is crucial to minimize prolonged stock-outs and ensure continuity of supply for these essential OTC products. Regulatory affairs heads should prepare for expedited review processes with the FDA for any new supplier qualifications, emphasizing the public health need.
Broader Regulatory Context: A Trend of Sterility Assurance Challenges
While ChemLifeIntel's knowledge graph does not detail specific prior regulatory actions for K.C. Pharmaceuticals, Inc., this recall occurs within a broader industry context of heightened FDA scrutiny on sterility assurance. Recent parallel events highlight a systemic challenge in sterile manufacturing across the pharmaceutical sector. For instance, Essential Wellness Pharma faced an FDA Class II recall for its Progesterone Injection due to similar sterility assurance failures, as reported on June 15, 2026. Just days prior, on June 10, 2026, Spectra Medical Devices also initiated a Class II recall for Lidocaine HCl Injection, citing sterility assurance deficiencies. These incidents, alongside the K.C. Pharmaceuticals, Inc. recall, signal a clear regulatory focus from the FDA on ensuring the integrity of sterile drug products. For regulatory affairs and quality assurance leaders, this trend necessitates a proactive review of all sterile manufacturing processes, including environmental monitoring, aseptic processing controls, and terminal sterilization validation. The FDA's consistent enforcement actions indicate a low tolerance for deviations in sterility, making robust preventative measures and continuous improvement programs non-negotiable for any company involved in sterile drug production or distribution.
Remediation and Future Regulatory Outlook for K.C. Pharmaceuticals, Inc.
As an ongoing Class II recall, K.C. Pharmaceuticals, Inc. is now under significant FDA scrutiny to address the "Lack of Assurance of Sterility." The firm is expected to conduct a thorough root cause analysis to identify the precise origin of the sterility failure, which could range from issues in raw material quality, manufacturing processes, environmental controls, or packaging integrity. Following this, a comprehensive Corrective and Preventive Action (CAPA) plan must be developed and implemented. This plan will need to detail specific actions to rectify the identified deficiencies, prevent recurrence, and ensure the sterility of future product batches. The FDA will closely monitor the firm's remediation efforts. Failure to adequately address the root cause and implement effective CAPAs could lead to further escalated regulatory actions, including the issuance of an FDA Warning Letter, placement on an Import Alert (though this is a U.S. domestic recall, it sets a precedent for future international scrutiny), or even legal injunctions preventing further manufacturing and distribution. For business development executives and supply chain VPs, the long-term viability of K.C. Pharmaceuticals, Inc. as a reliable supplier will hinge on the speed and efficacy of its remediation. Companies should anticipate potential delays in future product availability from this manufacturer and factor this into their strategic planning and risk assessments.